Crossmark

Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study

Crossref DOI link: https://doi.org/10.1038/s41467-024-51536-x

Published Online: 2024-08-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Xiaojing

Ai, Luoyan

Hu, Keshu

Liang, Li https://orcid.org/0000-0002-1694-380X
Lv, Minzhi

Wang, Yan

Cui, Yuehong

Li, Wei

Li, Qian

Yu, Shan

Feng, Yi

Liu, Qing

Yang, Ying

Zhang, Jiao

Xu, Fei

Yu, Yiyi

Liu, Tianshu https://orcid.org/0000-0002-2318-2869
License Information

Text and Data Mining valid from 2024-08-23

Version of Record valid from 2024-08-23
More Information

Article History

Received: 9 March 2024

Accepted: 12 August 2024

First Online: 23 August 2024

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below